CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV90 ...
Phase 1
San Antonio, Texas, United States and 21 other locations
Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpos ...
Phase 2
San Antonio, Texas, United States and 83 other locations
the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...
Phase 2
San Antonio, Texas, United States and 46 other locations
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...
Phase 3
San Antonio, Texas, United States and 106 other locations
(PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing hig...
Phase 3
San Antonio, Texas, United States and 298 other locations
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With C...
Phase 2
San Antonio, Texas, United States and 73 other locations
phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian...
Phase 1
San Antonio, Texas, United States of America and 14 other locations
as a monotherapy and in combination with bevacizumab (or a biosimilar) in patients with locally advanced or metastatic solid tumors, including ovarian...
Phase 1, Phase 2
San Antonio, Texas, United States and 9 other locations
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the s...
Phase 2
San Antonio, Texas, United States and 69 other locations
HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody...
Phase 1
San Antonio, Texas, United States and 11 other locations
Clinical trials
Research sites
Resources
Legal